Literature DB >> 22155411

Design of a pediatric oral formulation with a low proportion of hydrochlorothiazide.

A Santoveña1, Z Hernández-Paiz, J B Fariña.   

Abstract

It is a normal pediatric practice in community and hospital pharmacies to prepare a new drug formulation when no commercial forms of it are available. Any dose or stability control is usually done for these types of compounding formulations due to the effort which means to develop these types of tests in pharmacies. We have studied five different hydrochlorothiazide oral formulations prepared with traditional compounding techniques in pharmacies to treat heart failure and edemas in babies. A Standard Operating Procedure (SOP) was done for every suspension. After the strictly monitoring of the SOP, every suspension was subjected to quality control tests (pH, particle size, viscosity, dose content and stability). There is only one studied formulation that guarantees the correct dose administering and stability after 3 weeks stored at 5 °C and light protected. Both, the percentage of wetting agent and the viscosity of the suspensor vehicle in this formulation make the correct dose administering possible after the formulation is shaken.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22155411     DOI: 10.1016/j.ijpharm.2011.11.034

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  5 in total

1.  Pediatric clinical pharmacology: an introduction to a series of educational papers.

Authors:  Karel Allegaert
Journal:  Eur J Pediatr       Date:  2013-01-05       Impact factor: 3.183

2.  Neonates need tailored drug formulations.

Authors:  Karel Allegaert
Journal:  World J Clin Pediatr       Date:  2013-02-08

Review 3.  Neonatal drug therapy: The first frontier of therapeutics for children.

Authors:  K Allegaert; J van den Anker
Journal:  Clin Pharmacol Ther       Date:  2015-07-22       Impact factor: 6.875

4.  Design, characterization and in vivo evaluation of nanostructured lipid carriers (NLC) as a new drug delivery system for hydrochlorothiazide oral administration in pediatric therapy.

Authors:  Marzia Cirri; Lavinia Maestrini; Francesca Maestrelli; Natascia Mennini; Paola Mura; Carla Ghelardini; Lorenzo Di Cesare Mannelli
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

Review 5.  Excipients in the Paediatric Population: A Review.

Authors:  Khadija Rouaz; Blanca Chiclana-Rodríguez; Anna Nardi-Ricart; Marc Suñé-Pou; Dèbora Mercadé-Frutos; Josep María Suñé-Negre; Pilar Pérez-Lozano; Encarna García-Montoya
Journal:  Pharmaceutics       Date:  2021-03-13       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.